Case Reports
. 2010 Nov;3(2).
doi: 10.1159/000319020.

The Clinical Importance of the Heterogeneity of HER2 neu

Enrique Davila 1 Kip Amazon  
  • PMID: 21045934
  •     8 References
  •     4 citations


We report on a patient with breast cancer in whom there were areas of the tumor that were 3+ positive and negative for HER2 neu by immunohistochemistry, adjacent to each other. Depending on the area tested the results were completely different. The clinical implications are important. We recommend retesting a large portion of the tumor in all cases of initially negative test results.

Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.
Sabine Glöckner, Hilke Buurman, +2 authors, Hans Kreipe.
Lab Invest, 2002 Oct 16; 82(10). PMID: 12379776
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.
Gail H Vance, Todd S Barry, +7 authors, College of American Pathologists.
Arch Pathol Lab Med, 2009 Apr 28; 133(4). PMID: 19391661
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
Jason T Lewis, Rhett P Ketterling, +3 authors, Daniel W Visscher.
Am J Clin Pathol, 2005 Jul 26; 124(2). PMID: 16040300
Trastuzumab--mechanism of action and use in clinical practice.
Clifford A Hudis.
N Engl J Med, 2007 Jul 06; 357(1). PMID: 17611206
Highly Cited. Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Edith A Perez, Vera J Suman, +7 authors, Robert B Jenkins.
J Clin Oncol, 2006 Jul 01; 24(19). PMID: 16809727
Highly Cited.
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Harold J Burstein, Lyndsay N Harris, +14 authors, Eric P Winer.
J Clin Oncol, 2002 Dec 31; 21(1). PMID: 12506169
Tumour heterogeneity and immune-modulation.
Mariam Jamal-Hanjani, Eirini Thanopoulou, +2 authors, Charles Swanton.
Curr Opin Pharmacol, 2013 May 15; 13(4). PMID: 23664091    Free PMC article.
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry.
Charlotte Giesen, Hao A O Wang, +11 authors, Bernd Bodenmiller.
Nat Methods, 2014 Mar 04; 11(4). PMID: 24584193
Highly Cited.
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
Peter A Kaufman, Kenneth J Bloom, +11 authors, Charles L Vogel.
Cancer, 2014 Jun 17; 120(17). PMID: 24930388    Free PMC article.
Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer.
Helena Skálová, Nikola Hájková, +3 authors, Ivana Tichá.
Exp Ther Med, 2019 Oct 02; 18(4). PMID: 31572543    Free PMC article.